Details

Autor(en) / Beteiligte

• Ponomareva, I V
• Stepanova, S B
• Reneva, S A
• Sorokova, E V
• Vagina, M A
• Makodzeba, O A
• Galiullin, T R

Titel

Possibilities of optimizing therapy in COVID-19 survivors with focal epilepsy

Ist Teil von

• Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023, Vol.123 (3), p.130

Ort / Verlag

Russia (Federation)

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To study the effect of phenosanoic acid therapy on the frequency of seizures, asthenia and quality of life of adult patients with focal epilepsy who had a new coronavirus infection caused by SARS-CoV-2. The data of 20 patients with focal epilepsy who suffered COVID-19 and received therapy with phenosanic acid (Dibufelon) were studied. The frequency of epileptic seizures, the severity of asthenia and the quality of life were evaluated according to clinical scales. Significant decrease in the frequency of bilateral tonic-clonic seizures and focal seizures with loss of consciousness was recorded. There was a significant improvement in the quality of life. There was no significant dynamics of asthenia against the background of taking the drug phenosanic acid in patients. The preparation of phenosanic acid can be an effective means of add-on therapy in patients with epilepsy who have undergone COVID-19.